NEW YORK (GenomeWeb News) – Canadian diagnostic test developer Miraculins said today that it has partnered with Inverness Medical Innovations to commercialize Miraculins' suite of biomarkers for preeclampsia.

Under the collaborative research and option agreement, Inverness, through its Biosite division, will develop tests for Miraculins' panel of 35 biomarkers involved in placenta development and the occurrence of preeclampsia, a potentially fatal pregnancy complication.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.